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A bs tr ac t

Background
Bivalirudin, as compared with heparin and glycoprotein IIb/IIIa inhibitors, has been shown to reduce rates of bleeding and death in patients undergoing primary percutaneous coronary intervention (PCI). Whether these benefits persist in contemporary practice characterized by prehospital initiation of treatment, optional use of glycoprotein IIb/IIIa inhibitors and novel P2Y 12 inhibitors, and radial-artery PCI access use is unknown.
Methods
We randomly assigned 2218 patients with ST-segment elevation myocardial infarction (STEMI) who were being transported for primary PCI to receive either bivalirudin or unfractionated or low-molecular-weight heparin with optional glycoprotein IIb/IIIa inhibitors (control group). The primary outcome at 30 days was a composite of death or major bleeding not associated with coronary-artery bypass grafting (CABG), and the principal secondary outcome was a composite of death, reinfarction, or non-CABG major bleeding.
Results
Bivalirudin, as compared with the control intervention, reduced the risk of the primary outcome (5.1% vs. 8.5%; relative risk, 0.60; 95% confidence interval [CI] , 0.43 to 0.82; P = 0.001) and the principal secondary outcome (6.6% vs. 9.2%; relative risk, 0.72; 95% CI, 0.54 to 0.96; P = 0.02). Bivalirudin also reduced the risk of major bleeding (2.6% vs. 6.0%; relative risk, 0.43; 95% CI, 0.28 to 0.66; P<0.001). The risk of acute stent thrombosis was higher with bivalirudin (1.1% vs. 0.2%; relative risk, 6.11; 95% CI, 1.37 to 27.24; P = 0.007). There was no significant difference in rates of death (2.9% vs. 3.1%) or reinfarction (1.7% vs. 0.9%). Results were consistent across subgroups of patients. P rimary percutaneous coronary intervention (PCI), which is the standard of care for the treatment of patients with STsegment elevation myocardial infarction (STEMI), 1, 2 requires adjunctive antithrombotic treatment with anticoagulants and antiplatelet agents. In the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial, 3 bivalirudin (Angiomax, Angiox, the Medicines Company), as compared with unfractionated heparin and routine use of glycoprotein IIb/IIIa inhibitors, reduced rates of major bleeding and death at 30 days, with a survival benefit that extended to 3 years, 4 albeit with an increased rate of acute stent thrombosis.
A number of changes have occurred in clinical practice since the HORIZONS-AMI trial was conducted: the use of radial-artery PCI access, which may reduce the risk of bleeding and vascular complications, 5 has expanded; and the use of ticagrelor or prasugrel has been increasingly adopted. 6, 7 In parallel, the use of glycoprotein IIb/IIIa inhibitors has declined and is no longer routine. Anticoagulation is frequently started early, either because the patient presents at a hospital where PCI is not performed and thus requires transport to another hospital or -as is frequently the case in Europe -because treatment is started in the ambulance.
The European Ambulance Acute Coronary Syndrome Angiography (EUROMAX) trial, an international, randomized, open-label study, was designed to test whether bivalirudin, initiated during transport for primary PCI in patients with STEMI, was superior to heparins with optional use of glycoprotein IIb/IIIa inhibitors in contemporary practice, with frequent use of radial access and novel P2Y 12 inhibitors. 8 
Me thods
Study Design
The trial was designed by an academic executive committee (see the Supplementary Appendix, available with the full text of this article at NEJM .org) and the sponsor (the Medicines Company), with the latter collecting the data. An academic statistical group received data from the sponsor and provided data and analyses to the independent data and safety monitoring committee. At trial completion, data were analyzed by the sponsor and validated by an independent academic statistical group led by two of the authors that had the full data set.
The first author wrote the first draft of the manuscript, which was revised and approved by all coauthors, and provided for comment to the sponsor. Editorial support (limited to editing for style, referencing, and use of graphics) was provided by MedLink Healthcare Communications and was funded by the Medicines Company. The authors made the decision to submit the manuscript for publication; they accept full responsibility for the accuracy and completeness of the data and all analyses and for the fidelity of this report to the trial protocol, available at NEJM.org.
Study Patients
The study enrolled men and nonpregnant women (18 years of age or older) presenting within 12 hours after the onset of symptoms with a presumed diagnosis of STEMI, with any of the following conditions: ST-segment elevation of at least 1 mm in two contiguous leads on electrocardiography, presumed new left bundle-branch block, or ST-segment depression of at least 1 mm in at least two leads in V 1 through V 3 with a positive terminal T wave. All patients had to be scheduled for angiography with the intention of performing primary PCI within 2 hours after the first medical contact. The main exclusion criteria were treatment with any injectable anticoagulant before randomization, oral anticoagulation, recent surgery, and a history of bleeding. A full set of inclusion and exclusion criteria is provided in the Supplementary Appendix.
Patients were identified, initial consent was obtained, randomization was performed, and study-drug administration was initiated in the ambulance or in a non-PCI hospital. Patients were transported urgently to the primary PCI hospital, where treatment was continued and outcomes data collected. All patients initially provided abridged written or oral informed consent in the ambulance or non-PCI hospital before study-drug administration. This consent was subsequently confirmed by a more formal final written informed consent. The study was approved by local ethics committees and health authorities. 8 1.75 mg per kilogram per hour. The protocol specified that the infusion should be continued for at least 4 hours after PCI. The protocol also specified that the dose during the post-PCI interval should be 0.25 mg per kilogram per hour; however, continuation of the higher dose used during PCI was also permitted. Bailout use of a glycoprotein IIb/IIIa inhibitor was allowed in the event of giant thrombus or microvascular obstruction (no reflow).
Patients who were assigned to the heparin group (control group) received either unfractionated heparin (100 IU per kilogram without a glycoprotein IIb/IIIa inhibitor or 60 IU per kilogram with a glycoprotein IIb/IIIa inhibitor) or an intravenous bolus of enoxaparin (0.5 mg per kilogram). The use of glycoprotein IIb/IIIa inhibitors was left to physician preference and was categorized as either routine (started before PCI) or bailout. Any glycoprotein IIb/IIIa inhibitor could be used at the approved doses and regimens.
All patients received aspirin and an approved P2Y 12 inhibitor as early as possible after the first medical contact. Decisions regarding access site, performance of thrombus aspiration, and stent type were left to physician preference.
Study Outcomes
The primary outcome was a composite of death from any cause or major bleeding not related to coronary-artery bypass grafting (CABG) at 30 days. The principal secondary 30-day outcome was a composite of death from any cause, reinfarction, or non-CABG major bleeding. Other secondary end points included major adverse cardiovascular events (death, reinfarction, ischemiadriven revascularization, or stroke), net adverse clinical events (composite of major adverse cardiovascular events and non-CABG major bleeding), each of the components of the primary and principal secondary outcomes, ischemia-driven revascularization, stent thrombosis (as defined by the Academic Research Consortium 9 ), and a composite of reinfarction, ischemia-driven revascularization, or stent thrombosis.
The protocol definition of major bleeding was bleeding unrelated to CABG surgery that included intracranial, retroperitoneal, or intraocular bleeding; access-site hemorrhage requiring radiologic or surgical intervention; a reduction in the hemoglobin level of more than 4 g per deciliter (2.5 mmol per liter) without an overt source of bleeding; a reduction in the hemoglobin level of more than 3 g per deciliter (1.8 mmol per liter) with an overt source of bleeding; reintervention for bleeding; or use of any blood-product transfusion. Bleeding was also assessed according to Thrombolysis in Myocardial Infarction (TIMI) 10 and Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) 11 criteria. * There were no significant between-group differences except in the two categories that are noted below. CABG denotes coronary-artery bypass grafting, and IQR interquartile range. † Data on cardiac-related history were missing for one patient in each study group. ‡ P<0.05 for the between-group comparison. § Hyperlipidemia was defined as a diagnosis of hyperlipidemia or the use of lipid-lowering therapy. ¶ Killip classes are as follows: class I, no clinical signs of heart failure; class II, rales or crackles in the lungs, a third heart sound, and an elevated jugular venous pressure; class III, frank acute pulmonary edema; and class IV, cardiogenic shock or hypotension and evidence of peripheral vasoconstriction. ‖ Other countries include Austria, Czech Republic, Italy, Poland, and Slovenia. The primary study outcome was changed during the course of the trial. The original primary outcome measure was the composite of death from any cause, reinfarction, or non-CABG major bleeding, which became the principal secondary outcome after the change in the protocol. The change in the primary outcome was made in order to reduce the necessary sample size and occurred while the investigators were still unaware of study outcomes. Details of the circumstances surrounding the change in the primary outcome are provided in the Supplementary Appendix.
An independent clinical-events committee whose members were unaware of study-group assignments adjudicated deaths, bleeding episodes, reinfarction, ischemia-driven revascularization, stent thrombosis, and stroke. 8 Detailed definitions of all study end points are provided in the Supplementary Appendix.
Statistical Analysis
We determined that a sample size of 2200 patients would provide a power of 80% for determining the primary outcome at a two-sided alpha level of 0.05, assuming an event rate of 4.25% in the bivalirudin group and 7.0% in the control group. One planned interim analysis was performed by an independent statistician, after which the data and safety monitoring committee recommended that the trial continue as planned (see the Supplementary Appendix for details).
Analyses were performed in the intention-totreat population, which was defined as all patients who underwent randomization and provided written informed consent. We used the chi-square test to perform comparisons of event rates or Fisher's exact test in the case of sparse data. We used the log-rank test to compute the significance of time-to-event data. Continuous variables are reported as medians and interquartile ranges. Categorical variables are reported as frequencies and percentages. Analyses were performed with the use of SAS software, version 9.2. the Supplementary Appendix). Of these patients, 1102 were randomly assigned to the bivalirudin group and 1116 to the control group with optional receipt of a glycoprotein IIb/IIIa inhibitor. Of the 2218 patients who provided initial abridged informed consent, 2198 provided formal written informed consent (1089 in the bivalirudin group and 1109 in the control group); these patients were included in the intention-totreat population. The baseline characteristics of patients were generally well matched between the two groups, although there were higher rates of diabetes and previous myocardial infarction in the control group (Table 1) .
Treatments and Procedures
Treatments and procedures are summarized in Table 2 . The median time between study-drug initiation and coronary angiography was 50 minutes. There was similar use of femoral arterial access and radial access. 
Outcomes
The main trial outcomes are summarized in Table 3 and shown in Figure 1 , as well as in Figures  S2, S3 , and S4 in the Supplementary Appendix. The primary outcome occurred in 5.1% of the patients in the bivalirudin group and 8.5% in the control group with optional use of glycoprotein IIb/IIIa inhibitors (relative risk in the bivalirudin group, 0.60; 95% confidence interval [CI], 0.43 to 0.82; P = 0.001). The rate of occurrence of the principal secondary outcome was 6.6% in the bivalirudin group and 9.2% in the control group (relative risk, 0.72; 95% CI, 0.54 to 0.96; P = 0.02).
There was no significant difference in rates of death, regardless of whether the cause was cardiac or noncardiac. There was a lower rate of non-CABG major bleeding in the bivalirudin group than in the control group (2.6% vs. 6.0%; relative risk, 0.43; 95% CI, 0.28 to 0.66; P<0.001), as well as lower rates of TIMI major or minor bleeding and any GUSTO bleeding (Table 3) . Bivalirudin also reduced the rate of transfusion. Detailed information on individual types of bleeding events is provided in Table S1 in the Supplementary Appendix. There was no significant difference in rates of reinfarction, although the episodes were numerically more frequent in the bivalirudin group than in the control group.
Stent thrombosis was more frequent in the bivalirudin group than in the control group (1.6% vs. 0.5%; relative risk, 2.89; 95% CI, 1.14 to 7.29; P = 0.02); the difference was accounted for by stent thrombosis that occurred within 24 hours (Table 3) , with no significant difference in rates of subacute stent thrombosis (occurring within 30 days). The median time to acute stent thrombosis in the bivalirudin group was 2.3 hours (interquartile range, 1.8 to 2.8). None of the acute stent thromboses were fatal. One death was attributed to subacute stent thrombosis in the control group. Of the patients who had stent thrombosis, 65.2% had reinfarction and 100% had ischemia-driven revascularization associated with the stent thrombosis.
Sensitivity and Subgroup Analyses
Sensitivity analyses for the primary and principal secondary composite outcomes were performed in both the per-protocol population (all patients who underwent randomization, provided informed consent, received the randomized treatment, and underwent angiography) and the PCI population (all patients who underwent primary PCI) (Table S2 in the Supplementary Appendix). The results of these analyses were consistent with those in the intention-to-treat analysis.
An analysis of the effect of bivalirudin in 12 prespecified subgroups showed results that were consistent with those in the overall intention-totreat analysis with respect to the primary outcome (Fig. 2) , principal secondary outcomes ( CABG major bleeding (Fig. S6 in the Supplementary Appendix). In these analyses, there were no significant interactions with baseline or procedural variables, including the arterial-access site and type of P2Y 12 inhibitor that was administered. The effect of bivalirudin on the primary outcome appeared to be consistent regardless of whether patients in the control group received routine glycoprotein IIb/IIIa inhibitors (5.1% vs. 7.6%; relative risk, 0.67; 95% CI, 0.46 to 0.97; P = 0.03) or did not receive such therapy (5.1% vs.
9.8%; relative risk, 0.52; 95% CI, 0.35 to 0.75; P<0.001).
Discussion
In our study, prehospital initiation of bivalirudin, as compared with heparin with optional use of glycoprotein IIb/IIIa inhibitors, reduced the primary composite outcome of death or major bleeding at 30 days in patients with STEMI who were being transported for primary PCI. The secondary composite outcome of death, reinfarction, and major bleeding at 30 days was also reduced with bivalirudin. These benefits, which were consistent across subgroups, stemmed from substantial reductions in major bleeding. However, the risk of acute stent thrombosis was higher in the bivalirudin group. The HORIZONS-AMI trial showed that during primary PCI for STEMI, bivalirudin alone was superior to heparin plus a glycoprotein IIb/IIIa inhibitor, with a marked reduction in bleeding at 30 days. 3 There was also a reduction in the rate of death from cardiac causes and any cause, which was sustained for up to 3 years. 4, 12 Given evolving changes in clinical practice, our study was designed to determine whether these benefits of bivalirudin would persist in the contemporary setting. Important changes in this regard include prehospital initiation of intravenous anticoagulation, 13,14 increasing use of radial access for catheterization and PCI, 5, 15, 16 reduced use of glycoprotein IIb/IIIa inhibitors during primary PCI, 1, 2, 17 and the advent of the novel P2Y 12 inhibitors (ticagrelor and prasugrel 6,7 ).
In our study, the initiation of bivalirudin in the prehospital setting achieved substantial reductions in bleeding, regardless of the choice for arterial access or P2Y 12 inhibitor and even when the use of glycoprotein IIb/IIIa inhibitors was optional. However, at 30 days, we did not find the benefit of bivalirudin in reduced rates of death from cardiac and other causes that were seen in the HORIZONS-AMI trial. Data are currently being collected on 1-year mortality as a prespecified end point.
In the HORIZONS-AMI trial, there was an increased risk of acute stent thrombosis among patients receiving bivalirudin. The discontinuation of bivalirudin at the end of PCI and before the onset of the antiplatelet effect of oral P2Y 12 inhibitors may have created a vulnerable window for stent thrombosis. In contrast, in the heparin group, acute stent thrombosis was either minimized or delayed by the prolonged infusion of glycoprotein IIb/IIIa inhibitors. 18, 19 In our study, there was also a higher risk of acute stent thrombosis in the bivalirudin group, which suggests that neither a prolonged, reduced-dose infusion of bivalirudin nor the use of the new oral P2Y 12 inhibitors was sufficient to address this risk. Given the delayed onset of the antiplatelet effect of the oral P2Y 12 inhibitors in patients with STEMI, 20 avoiding the occurrence of stent thrombosis may require more potent and rapidly effective antithrombotic agents, such as intravenous antiplatelet drugs. 21,22 Our study showed a nonsignificant increase in rates of reinfarction and ischemia-driven revascularization in the bivalirudin group, which appeared to be driven primarily by the increased rate of acute stent thrombosis. However, our study was not powered to examine these outcomes separately.
Some limitations of our study should be taken into consideration. The primary composite outcome was changed in order to reduce the sample size as a consequence of slow enrollment. An open-label design was implemented because of the logistic impracticality of a double-blind design in the context of emergency transport for primary PCI in a multinational trial. To minimize reporting bias that can be associated with an open-label design, events were adjudicated blindly by an independent clinical-events committee that used standardized end-point definitions. The trial was not powered to examine 30-day mortality and its cardiac and noncardiac subsets. Although the use of anticoagulation before catheterization was a notable feature of our study, the trial was neither designed nor intended to compare such use with use in the catheterization laboratory. Finally, although the trial allowed for the use of either unfractionated heparin or enoxaparin, too few patients received the latter (which is an accepted option in Europe 1 ) to reliably test the consistency of the benefit among types of heparin.
In conclusion, in patients with STEMI who were being transported for primary PCI, bivalirudin, as compared with heparin with optional use of glycoprotein IIb/IIIa inhibitors, reduced 30-day rates of the primary and principal secondary outcomes, through a reduction in major bleeding, with higher rates of acute stent thrombosis.
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